On the other hand, despite the approval of the abovementioned combination regimens by the US Food and Drug Administration for the treatment of untreated EGFR-variant advanced NSCLC,23,24 monotherapy with third-generation EGFR TKI may still be a mainstay treatment in clinical practice,26 especially for patients who are intolerant to or refuse combination therapy. Here, EGFR is linked to non-small cell lung carcinoma.